As one of the most successful therapeutic target families, G protein-coupled receptors
(GPCRs) have experienced a transformation from random ligand screening to knowledge …

Unique, functional, homodimeric heavy chain–only antibodies, devoid of light chains, are
circulating in the blood of Camelidae. These antibodies recognize their cognate antigen via …

Repurposing drugs as treatments for COVID-19, the disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …

G protein-coupled receptors (GPCRs) are the most common proteins targeted by approved
drugs. A complete mechanistic elucidation of large-scale conformational transitions …

G protein-coupled receptors (GPCRs) are privileged structural scaffolds in biology that have
the versatility to regulate diverse physiological processes. Interestingly, many GPCR ligands …

Discovered more than 30 years ago, the angiotensin AT 2 receptor (AT 2 R) has evolved
from a binding site with unknown function to a firmly established major effector within the …

Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …

Over one-third of current drugs target G-protein-coupled receptors (GPCRs). Leveraging the
phenomenon of biased signaling, where different ligands that bind to the same GPCR …

Signaling-biased ligands acting on G-protein-coupled receptors (GPCRs) differentially
activate heterotrimeric G proteins and β-arrestins. Although a wealth of structural knowledge …

Rationale: Excessive Ang II (angiotensin II) levels lead to a profibrotic and hypertrophic
milieu that produces deleterious remodeling and dysfunction in hypertension-associated …